



(11) **EP 3 586 141 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
22.02.2023 Bulletin 2023/08

(45) Date of publication and mention
of the grant of the patent:
18.01.2023 Bulletin 2023/03

(21) Application number: **18705960.5**

(22) Date of filing: **27.02.2018**

(51) International Patent Classification (IPC):
G01N 33/576^(2006.01) G01N 33/68^(2006.01)

(52) Cooperative Patent Classification (CPC):
G01N 33/576; G01N 33/6893; G01N 2800/085;
G01N 2800/52; G01N 2800/56

(86) International application number:
PCT/EP2018/054809

(87) International publication number:
WO 2018/154140 (30.08.2018 Gazette 2018/35)

(54) **NON-INVASIVE DIAGNOSIS OF FIBROTIC NON-ALCOHOLIC STEATOHEPATITIS**

NICHT-INVASIVE DIAGNOSE VON FIBROTISCHER NICHTALKOHOLISCHER STEATOHEPATITIS (NASH)

DIAGNOSTIC NON-INVASIF DE LA STÉATOHÉPATITE NON ALCOOLIQUE (NASH) FIBROSANTE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **27.02.2017 US 201762464106 P**
24.05.2017 EP 17305615

(43) Date of publication of application:
01.01.2020 Bulletin 2020/01

(73) Proprietors:
• **Université d'Angers**
49000 Angers (FR)
• **Centre Hospitalier Universitaire d'Angers**
49100 Angers (FR)

(72) Inventor: **BOURSIER, Jérôme**
49320 Brissac-Quincé (FR)

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(56) References cited:
WO-A1-2013/049509 WO-A1-2014/049131

- **Stergios A Polyzos ET AL: "Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index Correspondence and reprint request", , 1 September 2013 (2013-09-01), pages 749-757, XP055391300, Retrieved from the Internet: URL:http://www.annalsofhepatology.com/revista/numeros/2013/06_135_v12n5_2013_AdipocytokinesCytokeratin.pdf [retrieved on 2017-07-17]**
- **FLORIANE RUDWILL ET AL: "Effect of enforced physical inactivity induced by 60-day of bed rest on hepatic markers of NAFLD in healthy normal-weight women", LIVER INTERNATIONAL, vol. 35, no. 6, 21 June 2015 (2015-06-21), pages 1700-1706, XP055391307, GB ISSN: 1478-3223, DOI: 10.1111/liv.12743**
- **HAMZA RT1 ET AL: "Serum Pentraxin 3 Fragment as a Noninvasive Marker of Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents", HORMONE RESEARCH IN PAEDIATRICS, S. KARGER AG, CH, vol. 86, no. 1, 17 June 2016 (2016-06-17), pages 11-20, XP009504148, ISSN: 1663-2818, DOI: 10.1159/000446566**

EP 3 586 141 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).